The European Union (EU) is steadily making progress on the Artificial Intelligence Act (AI Act), landmark legislation that will affect AI not just for medical uses, but for all uses across the EU economy.
The controversy over the use of paclitaxel (PTX) in devices used to treat peripheral artery disease (PAD) has taken roughly half a decade to unwind as regulatory agencies across the globe stand down their restrictions on the use of these devices.
In the first month of 2024, med-tech financings passed the $1 billion mark once more, raising a total of $1.06 billion through 46 transactions recorded by BioWorld. It was the fourth consecutive month where med-tech financings exceeded the $1 billion threshold, just slightly down from the $1.07 billion raised in December.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acarix, Carthera, Dilon, Element Biosciences, Genesis Medtech, Hamilton Beach, Healthbeacon, Inovalon Holdings, Integrated DNA, Microbot Medical, Nanostring Technologies, Sifi, Vigilanz.
The week closed out with two IPOs on their way in. Alto Neuroscience Inc. (NASDAQ:ANRO) and Fractyl Health Inc. (NASDAQ:GUTS) both debuted on Wall Street with offerings looking to raise combined $238.6 million.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bruin Biometrics, Clincierge, Greenphire, Maxim Biomedical, Myriad Genetics, Pixium, Theryq, United Imaging.
RSS
